产品
编 号：F183297
分子式：C16H10FNO3
分子量：283.25
分子式：C16H10FNO3
分子量：283.25
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 154554-41-3
产品详情
生物活性：
CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity.
体内研究：
CHM-1 (10 mg/kg; I.p.) induces a dose-dependent inhibition of HA22T tumor growth.Animal Model:Male severe combined immunodeficient mice (HA22T)
Dosage:10 mg/kg
Administration:I.p.
Result:Induced a dose-dependent inhibition of HA22T tumor growth.
体外研究：
CHM-1 (0-100μM; 24 hours) induces significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells (IC50 = 0.75 μM).CHM-1 (0-10 μM; 24 hours) significantly increases the binding of cyclin B1 to Cdc2 in HA22T cells.
CHM-1, a microtubule-destabilizing agent, inhibits tubulin polymerization. CHM-1 is a potent and selective antimitotic antitumor activity against human hepatocellular carcinoma. CHM-1 induces growth inhibition and apoptosis via G2-M phase arrest in human hepatocellular carcinoma cells by activation of Cdc2 kinase activity.
体内研究：
CHM-1 (10 mg/kg; I.p.) induces a dose-dependent inhibition of HA22T tumor growth.Animal Model:Male severe combined immunodeficient mice (HA22T)
Dosage:10 mg/kg
Administration:I.p.
Result:Induced a dose-dependent inhibition of HA22T tumor growth.
体外研究：
CHM-1 (0-100μM; 24 hours) induces significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells (IC50 = 0.75 μM).CHM-1 (0-10 μM; 24 hours) significantly increases the binding of cyclin B1 to Cdc2 in HA22T cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备